Recent Updates
Recently added Catalysts
TELO Positive Sentiment

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Monday, September 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telomir Pharmaceuticals has announced promising research findings from The Ohio State University, showing that their compound Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models. This research supports the potential for further evaluation of Telomir-Zn as a therapeutic option. The collaboration highlights the company's commitment to advancing cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated in-vitro anti-cancer activity in osteosarcoma models.
  • Research conducted in collaboration with a reputable institution.
  • Potential for translational application in both human and canine patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
7.3%
average across 3 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Zn-Telomir
Phase 1 · Triple-Negative Breast Cancer (TNBC)

Full Press Release Details

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The findings establish a translational foundation for evaluating the compo…
You can read the full content here
The post Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models appeared first on Telomir Pharmaceuticals, Inc. (TELO) .

Frequently Asked Questions

What is Telomir-Zn?

Telomir-Zn is a compound developed by Telomir Pharmaceuticals targeting cancer growth.

What type of cancer models were used in the research?

The research utilized human and canine osteosarcoma models.

Which institution collaborated with Telomir Pharmaceuticals?

The Ohio State University College of Veterinary Medicine collaborated on the research.

What was the outcome of the research?

The research demonstrated that Telomir-Zn inhibits cell growth in osteosarcoma models.

ShareAdd on Google
Tags: TELO Viatris Investor Conferences Healthcare Telomir osteosarcoma Ohio State University anti-cancer
Last updated: Sep 14, 2026

Biotech snapshot

Cash runway
$5M liquidity · $0M/mo burn
~14 mo
Low dilution risk
Lead asset
Zn-TelomirPhase 1
Triple-Negative Breast Cancer (TNBC) →

Catalyst track record

+37%
best trade around TELO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for TELO.

See every catalyst's timing & PoA →